BiostealthAI® Secures European Patent Grant for Touchable Cardiovascular Surfaces.

LONDON, UK— May 6, 2026 — BiostealthAI has secured a European patent grant for Touchable Cardiovascular Surfaces, a surface-level physiological sensing architecture designed to enable cardiovascular signal acquisition through ordinary touch-based device surfaces.

TCS is designed to transform ordinary touch surfaces into contact-conditioned physiological interfaces while preserving the familiar behavior of the host surface. It achieves this through distributed photonic sensing locations that can be selected during touch, evaluated for signal suitability, and routed into a disciplined output stream aligned with host-system integration.

The architecture supports a product-agnostic approach to surface-level physiological measurement across consumer, enterprise, and industrial device environments.

The grant comes as BiostealthAI continues selective technical and commercial engagement with notebook OEM stakeholders regarding potential integration pathways for TCS in notebook trackpads, palm-rest regions, and other touch-based device surfaces. These discussions form part of the company’s broader licensing strategy for embedding physiological sensing capability into everyday human-interface surfaces.

BiostealthAI is continuing to advance its patent portfolio, validation work, and commercial pathway for TCS across consumer, enterprise, and industrial device environments.